Cover Image
Market Research Report
Product code
757885

Global Age Realated Vaccine Adjuvant Market 2019-2026

Published: | DataM Intelligence | Delivery time: 2 business days

Price

Back to Top
Global Age Realated Vaccine Adjuvant Market 2019-2026
Published: December 1, 2019
DataM Intelligence
Delivery time: 2 business days
  • ALL
  • Description
  • Table of Contents
Description

The Importance of Adjuvant research in the improvement of the vaccine has increased gradually due to the improper immunogenicity of innovative vaccine antigens. The market is expected to reach USD 765.5 Million by 2025, globally. Vaccine Adjuvant market will increase as adjuvants will be required to enhance and extend immune responses while decreasing the amount of antigen necessary in each dose. The slight immunogenicity of new and novel vaccine antigens has increased the significance of adjuvant research in vaccine development. There is a need for the development of safe and non-toxic adjuvants.

Also, the global market size of Vaccine Adjuvants was valued at USD XX million in 2018 and it is expected that it will grow with a CAGR of 10.16% in the forecast period 2019-2026. Rising of cervical cancer, infectious diseases such as Human Papillomavirus (HPV), HIV, tuberculosis, etc., and other fatal diseases are expected to boost the demand for vaccine adjuvants

Recent vaccine approvals:

Vaccine Company Year Approval Agency

Dengue (Dengvaxia) Sanofi 2015 COFEPRIS

DTPHibHepIPV (Vaxelis) Merck & Co., Inc., Sanofi 2016 EMA

HPV (Gardasil 9) Merck & Co., Inc. 2014 FDA

HPV (Gardasil) Controlled Temperature Chain Merck & Co., Inc. 2015 EMA

Meningococcal A (MenAfriVac) 5 µg dose for children under one year Serum Institute of India 2014 WHO

Meningococcal B (Trumenba) Pfizer 2016 FDA

Rabies Serum Institute of India 2016 CDSCO

Seasonal influenza (VaxiGripTetra) Sanofi 2016 Uk

DRIVERS:

  • Initiation of advanced vaccine adjuvant fosters the efficiency in avoidance of fatal diseases such as cancer.
  • New initiatives taken up by different organizations are expected to be the essential driver to improve the immunization.
  • Increasing prevalence of multiple chronic diseases accentuates the need for vaccination.

RESTRAINTS:

  • Shortage of healthcare infrastructure in emerging nations has the high disease rate but, due to lack of proper healthcare infrastructure, the survival rate is very less.
  • The government organizes immunization camp in some regions for specific diseases such as Polio. Also, the advanced types of vaccines for particular immunization towards fatal diseases such as cancer are very costly that limits their uses.

GEOGRAPHICAL ANALYSIS:

Millions of people in the underdeveloped countries, such as South Africa, Indonesia, Iraq, and Nigeria are still in a state of poverty. They have no facility to well-developed healthcare infrastructure, which limits the penetration of immunization. The Eastern-Mediterranean region has the highest prevalence of severe infectious diseases and cancer. Currently, 70% to 80% of the world population does not have sufficient healthcare facilities. Lack of government initiatives for betterment of healthcare infrastructure, especially in the remote geographical areas, leads to high-unmet healthcare needs. Whereas North America held the largest market share at XX% in 2018 followed by Europe

ESTIMATION OF MARKET BY A SEGMENTATION TYPE:

Pathogen market is valued at USD XX million in 2018 and is expected to grow at a CAGR of 11.55% from 2018 to 2025 to reach an estimated value of USD 176.2 million by 2025. Pathogen product type is expected to be the fastest growing segment over the forecast period. There are some naturally occurring pathogens that are used as adjuvants to trigger the innate or non-specific immune responses to vaccines. These innate immunity system influences adaptive immune system for longer protection against the pathogen. Some pathogenic adjuvants tested include Monophosphoryl Lipid A. It is combined with alum to produce AS04 adjuvant used in human papillomavirus vaccine Cervarix.

The Vaccine Adjuvant market is segmented into different categories on the basis of following parameters:

Segmentation by Type

  • Pathogen
  • Particulate
  • Adjuvant Emulsion
  • Combination
  • Others

Segmentation by Application

  • Cancer
  • Infectious Diseases
  • Others

Segmentation by Administration

  • Intradermal
  • Intranasal
  • Intramuscular
  • Oral
  • Others

Some leading players in Vaccine Adjuvant market are Adjuvance, GSK, Novartis/CSL, Brentagg, Avanti Polar Lipids, Invivogen, SPI Pharma, Novavax, and OZ Biosciences.

The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles. The report profiles the leading companies in Vaccine Adjuvant market are Adjuvance, GSK, Novartis/CSL, Brentagg, Avanti Polar Lipids, Invivogen, SPI Pharma, Novavax, and OZ Biosciences.

KEY CONTENT OF THE REPORT:

  • Most comprehensive study on Vaccine Adjuvant market to date.
  • Excel data sheet with thousands of data points of the Vaccine Adjuvant market - level 4/5 segmentation
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study
  • Product mapping in excel for the key Vaccine Adjuvant market of all major market players

TARGET AUDIENCE FOR THE REPORT:

  • Raw Material Suppliers/ Buyers
  • Product Suppliers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Table of Contents

Table of Contents

1 Methodology and Scope

  • 1.1 Research methodology
  • 1.2 Scope of the Report

2. Executive Summary

3. Industry Analysis

  • 3.1 Market Drivers
  • 3.2 Market Restraints
  • 3.3 Porters Five Forces Analysis
    • 3.3.1 Suppliers Power
    • 3.3.2 Buyer Power
    • 3.3.3 Industry Competition
    • 3.3.4 Threat of new Entrant
    • 3.3.5 Threat of Substitutes

4. Segmentation by Type

  • 4.1 Pathogen
  • 4.2 Particulate
  • 4.3 Adjuvant Emulsion
  • 4.4 Combination
  • 4.5 Others

5. Segmentation by Application

  • 5.1 Cancer
  • 5.2 Infectious Diseases
  • 5.3 Others

6. Segmentation by Administration

  • 6.1 Intradermal
  • 6.2 Intranasal
  • 6.3 Intramuscular
  • 6.4 Oral
  • 6.5 Others

7. Geographic Analysis

  • 7.1 North America
    • 7.1.1 United States
    • 7.1.2 Canada
    • 7.1.3 Mexico
    • 7.1.4 Others
  • 7.2 Europe
    • 7.2.1 United Kingdom
    • 7.2.2 Spain
    • 7.2.3 Germany
    • 7.2.4 France
    • 7.2.5Rest of Europe
  • 7.3 Asia-Pacific
    • 7.3.1 India
    • 7.3.2 China
    • 7.3.3 Australia
    • 7.3.4 Japan
    • 7.3.5 Rest of Asia-Pacific
  • 7.4 South America
    • 7.4.1 Brazil
    • 7.4.2 Argentina
    • 7.4.3 Rest of South America
  • 7.5 Rest of the World

8. Competitive Landscape

  • 8.1 Market Share Analysis
  • 8.2 Company Benchmarking
  • 8.3 Key Strategies Adopted by Major Companies

9. Company Profiles*

  • 9.1 Agenus
  • 9.2 Adjuvance
  • 9.3 GSK
  • 9.4 Novartis/CSL
  • 9.5 Brentagg
  • 9.6 Avanti Polar Lipids
  • 9.7 Invivogen
  • 9.8 SPI Pharma
  • 9.9 Novavax
  • 9.10 OZ Biosciences

10. Appendix

  • 10.1 Sources
  • 10.2 List of Charts
  • 10.3 Expert Panel Validation
  • 10.4 Disclaimer
  • 10.5 Contact Us